{
    "ticker": "RLYB",
    "name": "Rallybio Corp.",
    "description": "Rallybio Corp. is a biotechnology company focused on developing innovative therapies for rare diseases and conditions. Founded in 2020 and headquartered in New Haven, Connecticut, Rallybio aims to transform the treatment landscape for patients suffering from serious and often neglected conditions. The company leverages cutting-edge science and technology to create novel biologic therapies that address unmet medical needs. Rallybio's pipeline includes therapies targeting a range of diseases, including hematological and genetic disorders, with an emphasis on both safety and efficacy. The company collaborates with leading researchers and institutions to ensure that its product candidates undergo rigorous scientific evaluation, paving the way for potential breakthroughs in treatment. Rallybio is driven by a commitment to patient-centricity, striving to bring hope and improved quality of life to individuals facing rare and debilitating health challenges. The company is also dedicated to sustainability and ethical practices in its operations, actively seeking partnerships that align with its mission to innovate responsibly.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New Haven, Connecticut, USA",
    "founded": "2020",
    "website": "https://www.rallybio.com",
    "ceo": "Martin Mackay",
    "social_media": {
        "twitter": "https://twitter.com/Rallybio",
        "linkedin": "https://www.linkedin.com/company/rallybio/"
    },
    "investor_relations": "https://ir.rallybio.com",
    "key_executives": [
        {
            "name": "Martin Mackay",
            "position": "CEO"
        },
        {
            "name": "Rebecca O. Taub",
            "position": "CBO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "RLYB212",
                "RLYB331"
            ]
        }
    ],
    "seo": {
        "meta_title": "Rallybio Corp. | Innovating Therapies for Rare Diseases",
        "meta_description": "Explore Rallybio Corp., a biotechnology company committed to developing innovative therapies for rare diseases. Learn about our pipeline and mission.",
        "keywords": [
            "Rallybio",
            "Biotechnology",
            "Rare Diseases",
            "Therapeutics",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Rallybio known for?",
            "answer": "Rallybio is known for developing innovative therapies for rare diseases."
        },
        {
            "question": "Who is the CEO of Rallybio?",
            "answer": "Martin Mackay is the CEO of Rallybio Corp."
        },
        {
            "question": "Where is Rallybio headquartered?",
            "answer": "Rallybio is headquartered in New Haven, Connecticut, USA."
        },
        {
            "question": "What are some of Rallybio's product candidates?",
            "answer": "Some of Rallybio's product candidates include RLYB212 and RLYB331."
        },
        {
            "question": "When was Rallybio founded?",
            "answer": "Rallybio was founded in 2020."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "BMRN",
        "SNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BIIB"
    ]
}